Is This $2.4B Biotech About to Explode? + $MELI & $ISRG (E133)

About this episode

Three stocks, three debates, one ticking clock. This week on Wall Street Wildlife, Krzysztof drops a live biotech catalyst with a 24-hour window, Luke defends his 20-year 'sugar daddy' holding, and a Latin American e-commerce giant is quietly being stress-tested. Plus: Krzysztof reveals a wild AI experiment he's launching in public — and betting real money against it.

💊 Luke's been holding $ISRG since 2006 without selling a single share — but is robotic surgery's best growth already behind it, or is this still the future of medicine?

📊 Medtronic just got FDA clearance. Competition is finally arriving at Intuitive Surgical's door — and margins are showing it. How worried should long-term holders be?

🧬 Krzysztof makes a live, time-sensitive case for a $2.4B biotech with a catalyst dropping the very next day — and explains why the market may be badly mispricing it. $RLAY

🌐 $MELI is growing revenue at 49% year-over-year — so why has the stock been going south? Luke explains the deliberate margin sacrifice and why he's still buying anyway.

🧠 Luke admits he expects $MELI to keep falling for six months... and bought more anyway. Krzysztof calls this a contradiction. Luke disagrees. Who's right?

🤖 Krzysztof built an AI he named Samantha Rabbit, designed specifically not to lie to him — and he's putting $5/day on himself vs. the machine in a 6-month public stock-picking contest!

Segments:

00:00:00 Cold Open: The Future of Surgery & Live Biotech Catalyst

00:01:13 Intro + King of the Jungle Portfolio Review

00:05:52 Community Portfolio Update: 11 Nominations & Why Pitching Changes Everything

00:11:28 $ISRG Deep Dive: Is Intuitive Surgical Still Worth Owning After 20 Years?

00:20:28 $ISRG Bear Case: Competition, GLP-1s, and Flat Margins

00:30:46 Relay Therapeutics: The Biotech With a 24-Hour Catalyst

00:44:42 Relay Bear Case: One-Trick Pony or Magical Molecule?

00:54:48 $MELI Deep Dive: Is Mercado Libre's Investment Phase a Buying Opportunity?

01:05:37 $MELI Bear Case: Emerging Market Risk & Shrinking Margins

01:12:09 Big Reveal: Krzysztof Builds an AI Stock Picker & Bets Against It

**********

If you want to see our furry faces, this podcast is also available on YouTube at ⁠youtube.com/@WallStreetWildlife?sub_confirmation=1⁠

**********

SUPPORT THE SHOW AND BECOME A PATREON:

wallstreetwildlife.com

**********

Follow us at:

⁠⁠x.com/7LukeHallard

⁠x.com/7FlyingPlatypus

**********

Fiscal.AI is the Complete Stock Research Platform for fundamental investors. With its beautiful design and institutional-quality data, Fiscal AI is incredibly powerful and easy to use.

Get 15% off any premium plan with:

fiscal.ai/wildlife

**********

Monkey’s “Zen, Nietzsche, How to Live” Substack:

firephilosophy.substack.com

**********

To use the same portfolio tracking tool as Luke, check-out:

portseido.com/?fpr=lukehallard

**********

Disclosure: Wall Street Wildlife hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation

**********

Fed up with the stock market giving you a hard time?

- Invest like seasoned pros with over 40 years in the game

- Discover the world's leading companies

- Sharpen your best investing practices and ditch the worst

- Learn how to start investing

- Essential investing principles to boost your returns

Keywords:

$ISRG, $MELI, Relay Therapeutics, Intuitive Surgical, Mercado Libre, robotic surgery investing, biotech catalyst, PI3K inhibitor, GLP-1 impact on surgery, Latin America e-commerce, emerging market stocks, AI stock picking, position sizing, biotech binary event, razor and blades business model, gross margin compression, compounding stocks, long-term investing, King of the Jungle portfolio, community portfolio, Wall Street Wildlife, growth investing, contrarian biotech, clinical trial investing